Using Cannabinoids to Protect the Brain from Oxidative Stress
A government-owned patent describing how certain non-psychoactive cannabinoids can act as antioxidants to protect brain cells from damage caused by strokes, trauma, or diseases like Alzheimer's.
Original patent title: “Cannabinoids as antioxidants and neuroprotectants”
A government-owned patent describing how certain non-psychoactive cannabinoids can act as antioxidants to protect brain cells from damage caused by strokes, trauma, or diseases like Alzheimer's. Granted to US Department of Health and Human Services in 2003 with 29 claims and 78 forward citations, and it is now in the public domain.
Coverage
What does this patent actually cover?
This patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a method for treating diseases caused by oxidative stress—where unstable molecules damage cells—by using specific cannabinoids that do not bind to the NMDA receptor. Unlike traditional cannabinoids that cause a 'high,' the patent focuses on compounds like cannabidiol (CBD) that act as antioxidants to prevent neurological damage. The mechanism involves protecting the central nervous system during ischemic events, such as a stroke, or chronic conditions like Parkinson's disease. By avoiding NMDA receptor interaction, the method aims to provide neuroprotection without the psychoactive side effects or toxicity associated with other cannabis-derived compounds.
The gap
What does this patent NOT cover?
- Does not cover cannabinoids that act as antagonists at the NMDA receptor.
- Does not cover treatments for conditions unrelated to oxidative stress or neurodegeneration.
- Does not claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → the discovery of the cannabis plant itself, but rather a specific medical application of purified cannabinoid compounds.
- Does not cover psychoactive cannabinoids when used in a way that relies on their psychoactive properties.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The inventors identified that cannabinoids possess antioxidant properties independent of their well-known psychoactive effects, effectively decoupling the therapeutic benefit from the 'high' by targeting specific receptor profiles.
The Patent Drawing
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Epidiolex (a pharmaceutical-grade CBD)
Research into CBD for stroke recovery
Studies on neuroprotective agents for Alzheimer's disease
Why it matters
The bigger picture
This patent is significant because it was held by the U.S. government, highlighting early federal interest in the therapeutic, non-recreational potential of cannabinoids. It provided a scientific foundation for investigating CBD as a neuroprotectant, moving the conversation beyond the recreational use of THC. It remains a frequently cited document in the ongoing debate and research regarding the medical legalization and pharmaceutical development of cannabis-derived drugs.
Filed
April 21, 1999
Granted
October 7, 2003
Market context
Who's building on this
Companies in this space
Pharmaceutical companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) have built significant clinical programs around purified CBD, directly following the path of investigating non-psychoactive cannabinoids for neurological conditions. Various academic research institutions continue to cite this work when exploring the antioxidant pathways of phytocannabinoids.
Market impact
This patent helped legitimize the study of cannabinoids within the medical community by providing a clear biological mechanism—antioxidant neuroprotection—that is distinct from recreational use. It laid the groundwork for the eventual FDA approval of CBD-based therapies, shifting the perception of cannabis from a controlled substance to a potential source of novel pharmaceutical compounds.
Claim 1 — Plain English
What this patent covers
This patent claims a method for treating diseases caused by oxidative stress—where unstable molecules damage cells—by using specific cannabinoids that do not bind to the NMDA receptor. Unlike traditional cannabinoids that cause a 'high,' the patent focuses on compounds like cannabidiol (CBD) that act as antioxidants to prevent neurological damage. The mechanism involves protecting the central nervous system during ischemic events, such as a stroke, or chronic conditions like Parkinson's disease. By avoiding NMDA receptor interaction, the method aims to provide neuroprotection without the psychoactive side effects or toxicity associated with other cannabis-derived compounds.
The clever bit
The inventors identified that cannabinoids possess antioxidant properties independent of their well-known psychoactive effects, effectively decoupling the therapeutic benefit from the 'high' by targeting specific receptor profiles.
What it does not cover
- Does not cover cannabinoids that act as antagonists at the NMDA receptor.
- Does not cover treatments for conditions unrelated to oxidative stress or neurodegeneration.
- Does not claim the discovery of the cannabis plant itself, but rather a specific medical application of purified cannabinoid compounds.
- Does not cover psychoactive cannabinoids when used in a way that relies on their psychoactive properties.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
This patent is in the public domain
See the Freedom to Build guide — what is free to use, what is not, and how to cite this patent.
PatentBrief Score
Impact Score
Moderate
Citation count
38/40
Highly cited
Claim breadth
19/20
Very broad protection
Recency
0/20
Older than 20 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$132K – $421K
Midpoint $263K · expired or expiring · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Patent Claims
0 independent claims · 1 dependent
Claims are the legal boundaries of the patent. An independent claim stands alone. A dependent claim adds limitations to its parent, narrowing — but not broadening — the scope.
The original legal language
Original claims
29 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Axelrod, J., Grimaldi, M., & Hampson, A. J. (2003). Using Cannabinoids to Protect the Brain from Oxidative Stress (U.S. Patent No. 6,630,507). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/6630507/cannabinoids-as-antioxidants-and-neuroprotectants
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US6630507"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 20220304938 · Nanosphere Health Sciences
Tiny Lipid Balls for Precise, Better-Absorbed Cannabinoid Medicine
US 8399514 · 2013 · Biogen Idec MA Inc
Using Dimethyl Fumarate to Treat Multiple Sclerosis
US 10914745 · 2021 · Randox Laboratories
Using Blood Markers to Diagnose Stroke and Tell Its Type
US 8822430 · 2014 · Gilead Pharmasset LLC
Chemical Compounds for Treating Hepatitis C Virus
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Using Cannabinoids to Protect the Brain from Oxidative Stress cover?
A government-owned patent describing how certain non-psychoactive cannabinoids can act as antioxidants to protect brain cells from damage caused by strokes, trauma, or diseases like Alzheimer's.
Who owns patent US 6630507?
US Department of Health and Human Services owns this patent, granted in 2003.
When does this patent expire?
This patent has expired and is now in the public domain — anyone can use the invention freely.
What is patent US 6630507 cited by?
This patent has been cited by 78 later patents that build on its ideas.
What problem does this patent solve?
This patent is significant because it was held by the U.S. government, highlighting early federal interest in the therapeutic, non-recreational potential of cannabinoids. It provided a scientific foundation for investigating CBD as a neuroprotectant, moving the conversation beyond the recreational use of THC. It remains a frequently cited document in the ongoing debate and research regarding the medical legalization and pharmaceutical development of cannabis-derived drugs.
What does this patent NOT cover?
Does not cover cannabinoids that act as antagonists at the NMDA receptor.
Same assignee
More from US Department of Health and Human Services
Patent monitoring